ADGRL1变种:从发育性和性脑病变到带有发烧的遗传性,再加上发烧性
Wenting Lei1,2, Yurong Xiong1,2, Yongyuan Shi1,2
1Department of Pediatrics, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Developmental medicine and child neurology
|June 27, 2024
概括
研究人员发现了一种新的ADGRL1基因变异,与发烧性发作加 (GEFS+) 的遗传性有关. 这一发现扩大了对ADGRL1的理解.
科学领域:
- 遗传学 是一个遗传学.
- 神经学 神经学
- 分子生物学分子生物学
背景情况:
- 目前尚不完全了解ADGRL1基因的表型谱.
- 了解的遗传基础对于诊断和治疗至关重要.
- 家庭发烧发作和未知病因的需要进一步的遗传研究.
研究的目的:
- 扩大与ADGRL相关的已知的表型谱1.
- 研究ADGRL1基因变异与之间的关系.
- 在患有ADGRL1变异的患者中探索基因型-表型相关性.
主要方法:
- 在115个家庭中进行了全外测序,这些家庭患有不明原因的或家族发烧发作.
- 使用in silico工具和蛋白质建模来预测已识别的变种的病原性.
- 对以前报告的和新发现的ADGRL1致病变体进行了全面分析.
主要成果:
- 一个新的ADGRL1变体 (p.Pro753Leu) 在一个患有发烧的遗传的家庭中被发现.
- 分析ADGRL1变异的16名患者中有6名患有,从性脑病变到GEFS+等.
- 与相关的ADGRL1变异主要是错误的,位于G蛋白结合受体自保护酶诱导域.
结论:
- ADGRL1是的潜在候选基因,包括GEFS+.
- 已识别的ADGRL1变异导致了一系列现象,从轻微的GEFS+到严重的脑病变.
- 变异的位置和基因型可能会解释ADGRL1相关患者的不同临床表现.
相关概念视频
Seizures: Classification
331
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
331
Arteries of the Lower Limbs
186
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
186
Antiepileptic Drugs: Glutamate Antagonists
317
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
317
Antiepileptic Drugs: GABAergic Pathway Potentiators
382
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
382
Inborn Errors of Metabolism
153
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
153
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
285
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
285


